Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883736 · ClinicalTrials.gov registry record · Early Phase 1
A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
A Early Phase 1 study of Acne Vulgaris, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 973
- Enrollment target
- 1
- Study location
NCT04883736: Completed Early Phase 1 study of Acne Vulgaris, sponsored by Sun Pharmaceutical Industries.
NCT04883736 is a Early Phase 1 study of Acne Vulgaris that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 973 participants, above the 261-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (273% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04883736, a Early Phase 1 study of Acne Vulgaris, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 973 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate the therapeutic equivalence and safety of Tretinoin Gel Microsphere, 0.1% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant) in the treatment of acne vulgaris.
Primary Outcome
Demonstration of Therapeutic Equivalence
Conditions Studied
Interventions
- DRUG Placebo Control
- DRUG Tretinoin Gel Microsphere, 0.1%
- DRUG RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%
Study Locations (1)
North Carolina
- Catawba Research, LLC - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 973 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2021-04-16 |
| Phase | Early Phase 1 |
What the finished NCT04883736 record still lists
NCT04883736 is an interventional study that assigns participants to a tested intervention. The registered 973 participants enrollment target is mid-sized for trials with a published cap, above the 261-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (273% higher).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which Placebo Control is the first listed.
NCT04883736 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04883736 about?
NCT04883736 is a clinical study titled "A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris". To demonstrate the therapeutic equivalence and safety of Tretinoin Gel Microsphere, 0.1% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant) in the treatment of acne vulgaris.
What is the current status of trial NCT04883736?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 973 participants. The study started on 2020-08-31. Estimated completion is 2021-04-16.
What conditions does trial NCT04883736 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT04883736?
The interventions under investigation include: Placebo Control (DRUG), Tretinoin Gel Microsphere, 0.1% (DRUG), RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (DRUG).
Who is sponsoring clinical trial NCT04883736?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04883736 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04883736's enrollment target sits among peer trials
973 4th of 67 higher than 64 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Weekly Isotretinoin vs Tetracycline for Moderate Acne
RECRUITING · Early Phase 1
-
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
COMPLETED · Early Phase 1
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Laser Treatment of Moderate to Severe Acne Vulgaris
ACTIVE NOT RECRUITING · NA
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI